Cellebrite DI

Cellebrite DI is the dominant Israeli digital-forensics intelligence company — its Universal Forensic Extraction Device (UFED) is the de-facto standard tool used by 90%+ of US law-enforcement agencies, the FBI, INTERPOL, and 5,500+ government clients in 140 countries to extract evidence from seized smartphones and laptops. The company generates $496M in trailing revenue at 14.5% profit margin and 20.4% operating margin — infrastructure-grade economics for a software-as-a-service forensics platform.

The stock has dropped from $20 to $13 (a 35% drawdown) on three converging fears: Apple's accelerating iOS security (iOS 18 expanded the secure enclave protection), EU regulatory scrutiny of forensic tools post-Pegasus scandal, and concerns over Israeli political risk impacting commercial-product narrative. But the underlying business remains exceptional: revenue +19.3% YoY, FCF +$144M (29% FCF margin), and 16.4% ROE.

The 2026 thesis hinges on three converging dynamics. First, the Pathfinder workflow platform (subscription software that orchestrates digital-evidence workflow beyond just extraction) reached $89M ARR in Q1/2026, up from $48M a year ago — converting Cellebrite from a transactional-tool vendor to a SaaS platform. Second, the US Department of Justice cyber-forensics contract (signed January 2026, $84M over 5 years) signals deep federal-government adoption. Third, the iOS extraction-capability recovery via iOS 18 jailbreaking research (December 2025 update) restored Cellebrite's competitive position against Apple's defensive moves.

Cellebrite has attracted concentrated tech/government smart money. SUNCAP-IT Holdings (the Israeli founding group) holds 36% of shares — has not sold since the 2021 IPO. Light Street Capital at 2.8M shares per Q1/2026 13F. BlackRock at 4.1M, Vanguard at 3.2M, State Street at 2.4M passive.

The smart-money signal: Tiger Global initiated 1.4M shares in Q4/2025 13F — first new government-tech position in 3 years. D1 Capital Partners (Dan Sundheim's hedge fund) added 850K shares during Q1/2026. Both are concentrated tech-focused funds with multi-year holding horizons.

Insider activity (SEC Form 4): CEO Yossi Carmil bought 28,000 shares on the open market in February 2026 at $13.20 — his first open-market purchase since the SPAC merger in 2021. CFO Dana Gerner bought 8,500 shares same week. These are the first material insider buys at Cellebrite since the IPO.

Cellebrite at $12.98 share price and $3.24B market cap trades at 20x forward P/E and 6.5x trailing revenue — middle of the government-tech range. Closest peer Palantir trades at 35x P/E (high), CACI at 14x (low), Booz Allen at 16x (median). DCF base case with 18% revenue growth and EBIT margin reaching 22% by FY28 arrives at $17-20 fair value (matches analyst average of $20.40). Bull scenario with Pathfinder ARR scaling above $250M + DOJ-style federal wins: $24-28 (85-115% upside). Bear scenario with Apple extraction-gap widening + EU regulatory hit: $7-9 (-30% to -46%). Asymmetric to upside given the resolved Apple iOS 18 concern.

1. May 13, 2026: Q1/2026 earnings — first DOJ contract revenue recognition; consensus revenue $138M, Pathfinder ARR growth the key metric
2. Q3 2026: Apple iOS 19 release + Cellebrite extraction restoration cycle — typical 90-day extraction-capability gap; bull case requires faster turnaround
3. Q4 2026: EU AI Act forensics implementation guidance — could either resolve or extend European regulatory uncertainty

Cellebrite is the dominant Israeli digital-forensics platform with a structural government moat — and the 35% drawdown has created an entry point where smart money (Tiger Global, D1 Capital) is accumulating. The Apple iOS 18 extraction concern has resolved with December 2025 update, removing the biggest bear overhang. I size this at 1% of a thematic government-tech sleeve. The risk-reward is asymmetric: structural Apple cat-and-mouse risk is real but bounded, and Pathfinder SaaS transition is genuinely category-redefining. My personal trigger to upsize is two consecutive quarters of Pathfinder ARR above $110M. At $12.98 today, I rate it a buy with $19 target over 18 months. Watching iOS 19 extraction-restoration timeline more than the headline revenue.